Quantcast

Latest Lupus erythematosus Stories

2011-03-09 17:26:00

First new lupus drug approved in 56 years SILVER SPRING, Md., March 9, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Benlysta (belimumab) to treat patients with active, autoantibody-positive lupus (systemic lupus erythematosus) who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Benlysta is delivered...

2011-03-09 14:22:00

Alliance For Lupus Research Commits $500,000 To Glean Genetic Basis For Lupus In African Americans And Other Ethnicities Powerful ImmunoChip Technology Expands Range of Testing NEW YORK, March 9, 2011 /PRNewswire-USNewswire/ -- The Alliance for Lupus Research (ALR) - the world's largest private funder of lupus research - today announced funding of an important new study to identify lupus susceptibility genes in multiple ethnicities including African Americans, who are three times more...

2011-02-04 01:04:17

Researchers at Dana-Farber Cancer Institute in Cambridge, Mass., in collaboration with Jackson Laboratory scientists, have identified a regulatory defect that drives lupus. Correcting the defect "may represent an effective therapeutic approach to systemic lupus erythematosus-like autoimmune disease," the researchers state in their research paper, published in the Proceedings of the National Academy of Sciences. The research team was led by Harvey Cantor, M.D., chair of the department of...

2010-12-14 15:15:00

HAYWARD, Calif., Dec. 14, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, has selected the Merck BioManufacturing Network in the UK, to manufacture the large scale GMP clinical and pre-commercial supplies of A-623, an investigational novel peptibody in development for a number of autoimmune diseases. "Establishing a rapid and high...

2010-12-09 16:00:00

Event Raises Crucial Funds for Lupus Research for 5 Million People Worldwide Living with Lupus NEW YORK, Dec. 9, 2010 /PRNewswire-USNewswire/ -- The Alliance for Lupus Research (ALR) honored Rupert Murdoch, News Corporation Chairman and CEO, at its 2010 One Love One Cause Gala event. Murdoch was recognized Wednesday, December 8, 2010 at the Mandarin Oriental Hotel with a 6:30pm reception and 8:30pm dinner and award presentation in honor of his support of the ALR. In attendance to honor...

2010-12-07 11:00:00

HAYWARD, Calif., Dec. 7, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that their product candidate varespladib (A-001) was awarded the 2010 European Society Pediatric Research Award at the Third Congress of the European Academy of Pediatric Societies 2010 in Copenhagen, Denmark where Dr. Daniele De Luca, MD, PhDst at the University Pope's Hospital and...

2010-11-16 17:05:00

NEW YORK, Nov. 16, 2010 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations are pleased with the U.S. Food and Drug Administration (FDA) Advisory Committee's vote to recommend approval of Benlysta(®) for active systemic lupus erythematosus (SLE), offering patients new found hope for the first approved treatment option in more than 50 years. The U.S. FDA Arthritis Advisory Committee voted 13 to 2...

2010-11-16 07:28:00

HAYWARD, Calif., Nov. 16, 2010 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that it has notified the US Food and Drug Administration (FDA) that the company has placed a voluntary hold on PEARL-SC, the Phase 2b study of A-623 for the treatment of Systemic Lupus Erythematosus (lupus), due to problems found with product vials. The company was...

2010-11-08 11:13:37

Lupus puts children at higher risk for coronary artery disease when they become adults, but routinely using statins doesn't provide enough benefit to warrant their regular use in children and adolescents, according to the largest study of pediatric lupus patients to date. Lupus is an autoimmune disease that causes widespread inflammation and organ damage. Children with lupus show early signs of atherosclerosis -- the fatty tissue buildup that is the precursor to clogged arteries. Previous...

2010-08-09 07:00:00

WALTHAM, Mass., Aug. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the systemic lupus erythematosus (SLE) drug market will quadruple from about $400 million in 2009 to more than $1.6 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related